Who is on it, and how far along Every drug ChEMBL records acting on PIK3CA, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved3 Alpelisib Alpelisib SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials45 Inavolisib Inavolisib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials32 Copanlisib Copanlisib SponsorBayer ModalitySmall molecule ActionInhibitor Open trials15 Phase 22 Serabelisib Serabelisib SponsorFaeth Therapeutics ModalitySmall molecule ActionInhibitor Open trials2 Fimepinostat Fimepinostat SponsorCuris, Inc. ModalitySmall molecule ActionInhibitor Open trials1 Phase 13 BAY-1082439 BAY-1082439 SponsorBayer ModalitySmall molecule ActionInhibitor Open trials0 PKI-179 PKI-179 SponsorWyeth is now a wholly owned subsidiary of Pfizer ModalitySmall molecule ActionInhibitor Open trials0 PWT-33579 PWT-33579 SponsorNot known ModalityOther ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-alpha subunit inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Oral GDC-0077 in Premature Ovarian Insufficiency Inavolisib Phase 1 Not yet recruiting Women's Hospital School Of Medicine Zhejiang University Oct 29, 2026 Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence Inavolisib — Recruiting Tianjin Medical University Cancer Institute and Hospital Sep 14, 2026 Alpelisib Challenge Test (ACT) Alpelisib Phase 1 Recruiting Columbia University Aug 21, 2026 A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies Alpelisib — Not yet recruiting Novartis Pharmaceuticals Aug 17, 2026 A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes Inavolisib Phase 2 Recruiting Hoffmann-La Roche Aug 5, 2026 A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients Inavolisib Phase 2 Not yet recruiting Fudan University Jul 10, 2026 Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib Phase 2 Not yet recruiting Novartis Pharmaceuticals Jul 1, 2026 EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC) Alpelisib — Recruiting Tel-Aviv Sourasky Medical Center Jun 12, 2026 A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Inavolisib Phase 2 Not yet recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Jun 1, 2026 Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy Alpelisib Phase 2 Not yet recruiting Wen-zhao ZHONG May 7, 2026 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib Phase 1 / Phase 2 Recruiting Faeth Therapeutics Apr 30, 2026 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs Alpelisib Phase 2 Recruiting Children's Hospital of Philadelphia Apr 22, 2026 A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer Inavolisib — Not yet recruiting xuliang Apr 21, 2026 Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 Inavolisib Phase 2 Not yet recruiting National Cancer Institute, Naples Apr 13, 2026 A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation Inavolisib Phase 2 Not yet recruiting Hu Hai Mar 2, 2026 EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) Alpelisib Phase 2 Recruiting Novartis Pharmaceuticals May 30, 2025 Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors Alpelisib Phase 1 / Phase 2 Recruiting Ensem Therapeutics May 29, 2025 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Serabelisib Phase 2 Recruiting Faeth Therapeutics Jun 17, 2024 Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) May 6, 2024 Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Apr 11, 2024 Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Fimepinostat Phase 2 Recruiting University of California, Los Angeles Aug 2, 2023 Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Aug 8, 2022 Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Phase 1 / Phase 2 Active, not recruiting City of Hope Medical Center Jun 25, 2021 Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib Phase 1 / Phase 2 Active, not recruiting Dana-Farber Cancer Institute Oct 1, 2020 Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Copanlisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Apr 15, 2020 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Copanlisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Mar 23, 2020 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Copanlisib Phase 1 / Phase 2 Active, not recruiting Brown University Feb 5, 2020
Show all 27Diseases most associated with it Open Targets association score, 0 to 1; all associations Megalencephaly-capillary malformation-polymicrogyria syndrome 0.85 Megalencephaly-capillary malformation-polymicrogyria syndrome Value0.85 CLOVES syndrome 0.80 CLOVES syndrome Value0.80 PIK3CA-related overgrowth spectrum 0.77 PIK3CA-related overgrowth spectrum Value0.77 Breast cancer 0.75 Breast cancer Value0.75 Open Cowden syndrome 5 0.75 Cowden syndrome 5 Value0.75 Ovarian cancer 0.73 Ovarian cancer Value0.73 Open Seborrheic keratosis 0.73 Seborrheic keratosis Value0.73 Breast adenocarcinoma 0.73 Breast adenocarcinoma Value0.73 CLAPO syndrome 0.72 CLAPO syndrome Value0.72 Pik3ca related overgrowth spectrum 0.72 Pik3ca related overgrowth spectrum Value0.72 Megalodactyly 0.68 Megalodactyly Value0.68 Hepatocellular carcinoma 0.67 Hepatocellular carcinoma Value0.67 Open Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4005 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P42336 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets